Vizimpro (Dacomitinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Vizimpro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Vizimpro is also referred to by its drug name, dacomitinib.

Vizimpro is a member of a class of drugs called tyrosine kinase inhibitors. Vizimpro is believed to work by inhibiting the activity of the human EGFR family of kinases (proteins). When mutated, these kinases are involved in the growth and spread of tumors.

How do I take it?
Prescribing information states that Vizimpro is taken orally as a tablet once daily, with or without food.

Vizimpro should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Vizimpro lists common side effects including diarrhea, rash, infection of the skin around the nails, inflammation of the mouth, decreased appetite, dry skin, weight loss, hair loss, cough, and itching.

Rare but serious side effects listed for Vizimpro include severe skin reactions, fetal harm, and interstitial lung disease (scarring of the lungs).

For more details about this treatment, visit:

Highlights of Prescribing Information — U.S. Food and Drug Administration

Dacomitinib (Oral Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in